- Rexahn's (RNN) Supinoxin (RX-5902) has so far shown to be "safe and well-tolerated" in an ongoing Phase I trial of patients with solid cancer tumors, with no drug-related side-effects reported.
- A fourth dosing cycle has been initiated following the completion of three cycles.
- In animal testing, treatment with Supinoxin resulted in a significant reduction in tumor growth.
- Shares jump 14.9%. (PR)
Rexahn cancer drug safe so far in Phase I study, shares jump
Recommended For You
About OCUP Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
OCUP | - | - |
Ocuphire Pharma, Inc. |